NCT02279537

Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD

A Retrospective and Prospective Non-interventional Open Label Study to Assess the Real Life of Treatment-naive Patients With Wet Age-related Macular Degeneration in Routine Clinical Practice in France and Starting an Anti VEGF Therapy With Aflibercept

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 593 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to collect real-life data on patients with wet age related macular degeneration (AMD) for whom treatment with Eylea was initiated

Detailed description

The study is both retrospective and prospective to collect local real life data on patients under routine treatment. The observation period starts on January 2014. Patients who have received the 1st injection with Eylea from January 2014 will be enrolled. Patients will be followed up for a period of 48 months or until it is no longer possible

Conditions

• Wet Macular Degeneration

Interventions

Type	Name	Description
DRUG	Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)	Administration by intravitreal injection

Timeline

• Start date: 2014-01-02
• Primary completion: 2019-04-17
• Completion: 2019-04-17
• First posted: 2014-10-31
• Last updated: 2023-11-07

Locations

1 site across 1 country: France